Compare Global X FTSE Southeast Asia ETF (ASEA) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Global X FTSE Southeast Asia ETF vs Enveric Biosciences Inc — how do they compare? Global X FTSE Southeast Asia ETF trades at $20.65, while Enveric Biosciences Inc trades at $1.34 (market cap $5.44M). The key difference: Global X FTSE Southeast Asia ETF is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| ASEA | ENVB | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $20.65 | $17.40 |
52-Week Low | $16.31 | $1.28 |
Market Cap | — | $5.44M |
Enterprise Value | — | $529.67K |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ASEA stock trades at $20.65, up 0.63% today, with a bullish technical signal from moving averages and neutral oscillators. The stock shows strong momentum with an ADX of 49.11 indicating a trending market. Recent corporate actions include a declared dividend of $0.41 per share scheduled for July 2026. Key support and resistance levels are clustered around $20-$21, suggesting a critical price zone for near-term direction.
The outlook remains cautiously optimistic given technical strength, but fundamental data is currently unavailable for a complete assessment. Risks include potential volatility near key technical levels and reliance on future financial performance disclosures. Investors should await upcoming earnings reports for clarity on valuation and profitability metrics.
ENVB trades at $1.35, down 5.59% today, with a bearish technical signal from moving averages. The company reported a net loss of $8.77M for 2025, though it beat EPS estimates in all four quarters. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003, including IND-enabling studies.
Outlook remains speculative with high financial risk due to negative ROE and ROA, but analyst consensus is 75% buy. Key risks include clinical trial outcomes and cash burn, while institutional interest is supported by a recent $13.9M private placement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global X FTSE Southeast Asia ETF
ASEA tracks the performance of the largest companies in Southeast Asia. It provides exposure to key emerging markets including Singapore, Indonesia, Thailand, and Malaysia, with a heavy focus on financials like DBS Group and Bank Central Asia.
Read more on ASEA →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
